ΠΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π΄ΠΎΠ±Π°Π²Π»Π΅Π½Π½ΡΠ΅ Π²ΠΈΠ΄Π΅ΠΎ:
pembrolizumab
-
6 Π»Π΅Ρ Π½Π°Π·Π°Π΄
1852 6 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 10:53ΠΠ΅ΡΠ²Π°Ρ Π»ΠΈΠ½ΠΈΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΏΠΎΡΠΊΠΈ. ΠΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡ ΠΏΠ΅ΠΌΠ±ΡΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π± ΠΈ Π°ΠΊΡΠΈΡΠΈΠ½ΠΈΠ±
-
2 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
7497 2 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 8:38#Pembrolizumab | Uses, Dosage, Side Effects and Mechanism | Keytruda
-
8 Π»Π΅Ρ Π½Π°Π·Π°Π΄
1643 8 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 18:21ΠΠΎΠ·Ρ ΠΈ ΡΠ΅ΠΆΠΈΠΌΡ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ ΡΠΎΡΠ΅ΠΊ: ΠΎΡΠ΅Π½ΠΊΠ° Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ 1-3 ΡΠ°Π·Ρ. ΠΠ΅ΠΌΠ±ΡΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±
-
3 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
1259 3 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 7:18KEYNOTE-826: pembrolizumab + chemotherapy vs placebo + chemotherapy for cervical cancer
-
5 Π»Π΅Ρ Π½Π°Π·Π°Π΄
2640 5 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 3:21ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study
-
4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
455 4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 5:54KEYNOTE-716: adjuvant therapy with pembrolizumab for patients with high-risk stage II melanoma
-
7 Π»Π΅Ρ Π½Π°Π·Π°Π΄
10614 7 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 2:38How Cancer Drug Keytruda ( Pembrolizumab) Treats Melanoma
-
7 Π»Π΅Ρ Π½Π°Π·Π°Π΄
403 7 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 1:06Dr. Whitman on the Role of Pembrolizumab in Melanoma
-
2 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
4257 2 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 2:13Neoadjuvant Pembrolizumab for Lung Cancer | NEJM
-
8 ΠΌΠ΅ΡΡΡΠ΅Π² Π½Π°Π·Π°Π΄
3805 8 ΠΌΠ΅ΡΡΡΠ΅Π² Π½Π°Π·Π°Π΄ 1:19Keytruda (pembrolizumab): Uses, How It Works, and Common Side Effects - Drugs.com
-
4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
124 4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 1:08KEYNOTE-716: safety profile and results of pembrolizumab for melanoma
-
1 Π³ΠΎΠ΄ Π½Π°Π·Π°Π΄
10847 1 Π³ΠΎΠ΄ Π½Π°Π·Π°Π΄ 1:44How does Keytruda Cancer Treatment Work?
-
1 Π³ΠΎΠ΄ Π½Π°Π·Π°Π΄
27929 1 Π³ΠΎΠ΄ Π½Π°Π·Π°Π΄ 4:27Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers
-
8 Π»Π΅Ρ Π½Π°Π·Π°Π΄
791 8 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 2:05Long-term efficacy of pembrolizumab in advanced melanoma
-
6 Π»Π΅Ρ Π½Π°Π·Π°Π΄
285 6 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 2:32Dr. Hamid on a Retrospective Analysis of Pembrolizumab in Melanoma
-
10 ΠΌΠ΅ΡΡΡΠ΅Π² Π½Π°Π·Π°Π΄
2362 10 ΠΌΠ΅ΡΡΡΠ΅Π² Π½Π°Π·Π°Π΄ 2:27ΠΠ±ΡΠ°Ρ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ ΠΏΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΏΠ΅ΠΌΠ±ΡΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ | NEJM